Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to -$11.2 million.

  • aTYR PHARMA's Net Cash Flow fell 33993.17% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year decrease of 58184.99%. This contributed to the annual value of -$12.0 million for FY2024, which is 19332.4% down from last year.
  • aTYR PHARMA's Net Cash Flow amounted to -$11.2 million in Q3 2025, which was down 33993.17% from $7.3 million recorded in Q2 2025.
  • In the past 5 years, aTYR PHARMA's Net Cash Flow ranged from a high of $57.6 million in Q3 2021 and a low of -$57.4 million during Q4 2021
  • Over the past 5 years, aTYR PHARMA's median Net Cash Flow value was -$378000.0 (recorded in 2024), while the average stood at -$425789.5.
  • In the last 5 years, aTYR PHARMA's Net Cash Flow plummeted by 468782.32% in 2021 and then soared by 237538.94% in 2025.
  • aTYR PHARMA's Net Cash Flow (Quarter) stood at -$57.4 million in 2021, then soared by 87.02% to -$7.5 million in 2022, then surged by 271.63% to $12.8 million in 2023, then plummeted by 102.96% to -$378000.0 in 2024, then plummeted by 2872.49% to -$11.2 million in 2025.
  • Its last three reported values are -$11.2 million in Q3 2025, $7.3 million for Q2 2025, and -$1.2 million during Q1 2025.